Quick search:
Content Search
Result Content Research
Result Content Research
1 How Many Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares Do Institutions Own?
2 Praxis Precision Medicines to Present at Upcoming Investor Conferences
3 Praxis Precision Medicines (PRAX) falls 0.51% to Close at $15.60 on July 30
4 May 11, 2021 Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
5 Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
6 Praxis Precision Medicines Inc. (PRAX) Q4 2020 Earnings Call Transcript
7 Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
8 May 13, 2021 Praxis Precision Medicines Prices Public Offering of Common Stock
9 Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
10 The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
11 April 14, 2021 Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment
12 Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
13 What Kind Of Shareholders Own Praxis Precision Medicines, Inc. (NASDAQ:PRAX)?
14 December 01, 2020 Praxis Precision Medicines Announces CFO Transition
15 Fresh Off a $110 Million Series C, Praxis Precision Medicines Eyes $190 Million IPO
16 Praxis Precision Medicines Expands Leadership Team to Advance its Pipeline for CNS Disorders
17 Praxis Precision Medicines Announces $110 Million Financing
18 Praxis Precision Medicines Receives Rare Pediatric Disease
19 Who Has Been Buying Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares?
20 Praxis Precision Medicines upsizes IPO by 35%, now looks to raise up to $180 million
21 Praxis Precision Medicines (PRAX) Plans Public Offering of Common Stock
22 Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters
23 Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders
24 The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
25 November 17, 2020 Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment
26 Praxis Precision Medicines Readies $126 Million IPO
27 The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
28 Praxis Precision Pops 62% as Biotech IPO Party Continues
29 PRAX Stock Forecast, Price & News (Praxis Precision Medicines)
30 Praxis Precision Medicines launches with $100M and bold sights on long-evasive neurological disorders
31 The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
32 Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
33 Praxis Precision Medicines Promotes Business Leader Stuart Chaffee to Chief Financial Officer
34 Why Is Coupa Software (COUP) Up 27.6% Since Last Earnings Report?
35 A few months after emerging from stealth, Praxis is handed a clinical hold for lead depression drug
36 Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
37 How to Optimize Success in Clinical Trials of Antidepressants
38 Hummingbird Bioscience buzzes with $125M series C led by Novo Holdings
39 Using AI/ML to reduce the costs and risks of CNS diseases research
40 Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease :: Scrip
41 Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy :: Scrip
42 Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer
43 The Petri Dish: NeuroBo acquires year-old startup; two biotechs launch
44 2021 Major Depressive Disorder Pipeline Insight Report: Insights for Approx 50+ Companies and 50+ Pipeline Drugs
45 Movers & Shakers, May 28 | BioSpace
46 Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors PRNewsWire
47 Taking A Life Science Company Public During A Pandemic
48 51 Biggest Movers From Yesterday – Benzinga
49 Endowment Sells Off Stocks in Major Technology Companies, Invests in Microsoft and Biopharmaceutical Companies in Fourth Quarter | News
50 The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
51 The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
52 The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit
53 30 Stocks Moving In Wednesday's Mid-Day Session
54 Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
55 The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
56 PTC Therapeutics Announces Management Change
57 Foghorn Therapeutics Rises 13% in Market Debut
58 Epilepsy Pipeline Review 2020: Therapeutic Analysis Report Featuring 140+ Companies & Drug Profiles
59 Codiak BioSciences Stock Falls in Market Debut
60 Q-State Biosciences Announces the Appointment of Biopharma Veteran Paul Medeiros as President and Chief Executive Officer
61 The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
62 Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021
63 Boeing, Galapagos, Intuitive Surgical: What to Watch When the Stock Market Opens Today
64 The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
65 Hearing-Aid Maker Eargo Soars 87% in Its First Trading Day
66 The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
67 06.21.21 -- FDA's Safety And Performance-based Pathway
68 Seeking Alpha Catalyst Watch
69 2020 Epilepsy Pipeline Conference
70 Outside GC Expands Life Sciences Team to Meet Growing Industry Demand
71 Clean tech is getting a fresh slate in 2020
72 FDA panel considering Alkermes' combo tablet in schizophrenia, bipolar I
73 Recursion CSO heads west for mini-brain upstart; Novartis vet steps up to the plate as CFO for Andrew Hirsch at C4 Therapeutics
74 Genentech alum Jane Grogan goes startup hopping from ArsenalBio to Graphite Bio; Scott Holmes to handle CFO duties at Catamaran Bio, teaming up again with ex-Disarm CEO
75 Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures
76 Axsome Therapeutics (AXSM) Receives a Buy from William Blair
77 Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
78 Automated and Closed Cell Therapy Processing Systems Markets, 2030
79 A pair of Bayer execs land promotions in the US; Energized by lenzilumab data, Humanigen taps AstraZeneca alum as CMO
80 WorkBoard's new chat-first experience makes OKR adoption easier than ever
81 60 Stock Price Gainers And Losers (March 19, 2021)
82 Stocks That Hit 52-Week Highs On Friday
83 The 14 Largest US Tech Startup Funding Rounds of July 2020
84 Branching Out in the Area of Genetic Neurology: Collaborating with Australian Clinical Trial Experts, Upcoming Webinar Hosted by Xtalks
85 Business Advisory Board
86 How a New York private equity giant became Boston’s biggest commercial landlord and biotech investor
87 Worldwide Depression Pipeline Guide, H1 2020: Therapeutics,
88 Bio Roundup: Cerevel's Shell, Thrive's Rise, Drug Price Drama & More
89 Bio Roundup: MESO's Miss, Pfizer's Cancer Bet, Vaccine Promise & More
90 Vedanta Biosciences taps Big Pharma vet Jeffrey Silber as CMO; Robert Doebele leaves behind teaching post at Colorado to focus on CSO job at Rain Therapeutics
91 Gene Therapy Shows Initial Promise for Parkinson's Disease
92 With GlaxoSmithKline in the rearview mirror, Abbas Hussain is ready to lead a biotech of his own; Doug Treco scores first CEO job since Ra Pharma buyout
93 Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation
94 Orphazyme Stock Sale Reaps $83M as Neimann-Pick Drug Review Begins
95 TNH's 50 Wealthiest Greeks in America List 2021: Numbers 30-21 | community , general news
96 Coupa Software Reports First Quarter Fiscal 2022 Financial Results
97 Stocks That Hit 52-Week Highs On Tuesday – Benzinga – Benzinga
98 AskBio Partners with TPG and Vida Ventures
99 Vida Ventures Unveils Next-Generation Life Sciences Venture Firm with $295 Million Under Management and an Investment in Allogene Therapeutics
100 Our First Look At Relmada Therapeutics